Core Insights - Ginkgo Bioworks has announced a collaboration with the European Health and Digital Executive Agency (HaDEA) to develop rapid metagenomic next-generation sequencing (mNGS) solutions for identifying respiratory pathogens, with funding of up to €24 million over four years [1][2][6] Group 1: Project Overview - The project, named RApid Next Generation Sequencing for Effective Medical Response (RANGER), aims to create a point-of-care mNGS solution that allows for rapid diagnostics of respiratory viruses, potentially transforming the diagnostic landscape [2][3] - The device is designed to provide a turnaround time of 6 hours, enabling hospitals to triage patients more effectively and reduce the burden of prolonged isolation and costly inpatient stays [3][6] Group 2: Technological Capabilities - The RANGER device will utilize "agnostic diagnostics," allowing it to sequence and identify virtually any respiratory pathogen, which enhances pandemic preparedness [4][6] - The program includes the option for the European Commission to procure 200 devices at preferred pricing, facilitating widespread deployment across EU/EEA healthcare systems [4] Group 3: Implementation Phases - The project will be executed in three phases, starting with the integration of existing technologies into a benchtop device, followed by clinical trials in EU hospitals, and concluding with securing EU certification for the device [5][6] Group 4: Strategic Alignment - This collaboration aligns with HERA's mission to strengthen Europe's capacity to respond to health emergencies by enhancing diagnostic capabilities and reducing delays in pathogen identification [6][7] - The initiative is expected to improve hospital triage, infection control, and provide early-warning tools against emerging pathogens, reinforcing the EU's health resilience [6][8]

Core Viewpoint - Acurx Pharmaceuticals has received a new patent in Japan for DNA Polymerase IIIC Inhibitors, which is crucial for the development of its antibiotic candidate ibezapolstat for treating C. difficile Infection (CDI) [1][2] Company Developments - Acurx has expanded its patent portfolio with three U.S. patents, one Israeli patent, and now a Japanese patent, all related to its ACX-375C program [1] - The company is preparing for Phase 3 clinical trials for ibezapolstat, having received positive regulatory guidance from the EMA [2][3] - The Phase 3 trials will involve approximately 450 subjects, randomized in a 1:1 ratio to receive either ibezapolstat or standard care vancomycin [3] Clinical Trial Insights - The Phase 2 clinical trial demonstrated a 96% Clinical Cure rate for ibezapolstat, with 100% cure in the Phase 2a segment [6][7] - The Phase 2b trial showed that ibezapolstat was well-tolerated, with no serious adverse events reported [7] - Ibezapolstat treatment led to favorable changes in bile acid metabolism, which may reduce the likelihood of CDI recurrence [8][12] Market Context - CDI is a significant healthcare issue, with estimates of 500,000 infections annually in the U.S. and a mortality rate of approximately 9.3% [11] - The CDC has classified C. difficile as an urgent threat, highlighting the need for new antibiotics [10] Product Overview - Ibezapolstat is a novel, orally administered antibiotic targeting Gram-positive bacteria, specifically designed to maintain a healthy gut microbiome while treating CDI [9][13] - The drug has received QIDP designation and Fast Track status from the FDA, which may expedite its development process [10]

Core Viewpoint - Ginkgo Bioworks Holdings, Inc. is set to host a presentation and Q&A session to review its business performance for Q4 and the full year of 2024 on February 25, 2025 [1] Group 1: Presentation Details - The presentation will begin at 5:30 p.m. ET and will be available on Ginkgo's investor relations website, with a replay option provided [2] - Questions can be submitted in advance via social media or email [2] Group 2: Company Overview - Ginkgo Bioworks is recognized as a leading platform for cell programming, offering comprehensive services across various sectors including food, agriculture, pharmaceuticals, and industrial chemicals [3] - The company is also focused on biosecurity, developing infrastructure and technologies to address biological threats [3]

Core Viewpoint - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a significant stock price increase of 14.5% to $16.36, driven by positive investor sentiment regarding its proprietary cell programming platforms and strong revenue growth expectations [1][2]. Company Summary - Ginkgo Bioworks utilizes its Foundry and Codebase platforms to offer R&D services under collaboration and license agreements, along with biomonitoring and bioinformatic support services to public health authorities [2]. - The company is projected to report a quarterly loss of $1.45 per share, reflecting a year-over-year increase of 59.7%, while revenues are expected to reach $45.08 million, marking a 29.7% increase from the previous year [3]. - The consensus EPS estimate for Ginkgo Bioworks has remained stable over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Context - Ginkgo Bioworks is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Krystal Biotech, Inc. (KRYS), that has shown a modest stock performance with a 0.7% increase [4]. - Krystal Biotech's EPS estimate has increased by 10.6% over the past month, indicating a significant year-over-year change of 330%, but it currently holds a Zacks Rank of 4 (Sell) [5].

Core Insights - Ginkgo Bioworks is launching the 2025 Ferment Series, an evolution of its annual conference aimed at advancing its mission of making biology easier to engineer [1][2] - The series will focus on specific areas within Ginkgo's cell engineering and biosecurity offerings, showcasing transformative solutions across various markets [2][3] Event Details - The Ferment Series will take place at Ginkgo's event venue in Boston's Seaport District, with a series of focused events throughout 2025 [1] - Each event will feature Ginkgo experts, partners, and industry leaders discussing applications of engineered biology [2] Technology and Innovations - Attendees will have the opportunity to see Ginkgo's technologies and innovations, including high-throughput AI-driven data generation services and automation systems [3] - New products and services will be highlighted, such as Ginkgo Datapoints and Ginkgo Biosecurity's monitoring and threat intelligence solutions [3] CEO Statement - Jason Kelly, CEO of Ginkgo Bioworks, emphasized the company's strengthened mission and the importance of showcasing their evolving platform and new capabilities at the 2025 Ferment events [4] 2025 Ferment Series Calendar - The series will include events focused on: - Summer: Datapoints x AI, focusing on data generation services and AI models for biotech R&D [5] - September: Ginkgo Biopharma Solutions, aimed at accelerating drug discovery and development [5] - October: Biosecurity, discussing strategies for biological risk management [5] - November: Automation, featuring demonstrations of Ginkgo's automation systems [6] Industry Engagement - Ginkgo will also participate in other industry conferences, such as World AgriTech and ABIM, to connect with partners and showcase its R&D capabilities [7][8]

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The ...

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRCBOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bio ...

Core View - Ginkgo Bioworks collaborates with Universal Cells, an Astellas company, to optimize next-generation iPSC-derived cancer cell therapies, leveraging Ginkgo's high-throughput biological approaches to address challenges in solid tumor therapy development [1] - The collaboration aims to enhance the potency and persistence of iPSC-derived immune cell therapeutics by combining Universal Cells' proprietary technologies with Ginkgo's expertise in CAR library design, screening, and immune cell engineering [2] Collaboration Details - The partnership focuses on improving the scalability and manufacturability of 'off-the-shelf' iPSC-derived cell therapies, which have the potential to transform cancer care [2] - Ginkgo's platform capabilities include CAR discovery and optimization, cell survival enhancement strategies, and gene editing tools for immune cell engineering, enabling rapid exploration and refinement of therapeutic designs [3] Ginkgo's Platform Strengths - Ginkgo employs computational tools, deep expertise in library assembly, and rigorous statistical analysis to accelerate the discovery and engineering of optimal therapeutic designs [3] - The company's high-throughput pooled and arrayed screening methods allow simultaneous testing of numerous CAR designs, aiming to improve immune cell persistence and functionality [3] Strategic Impact - The collaboration represents a significant milestone for Ginkgo as it expands its cell therapy portfolio and brings its immune cell engineering capabilities to a global pharmaceutical leader [4] - The partnership aims to optimize iPSC-derived allogeneic cell therapies, potentially improving patient outcomes and reshaping the treatment of solid tumors [4] Industry Context - Ginkgo Bioworks is a leading horizontal platform for cell programming, offering end-to-end services across diverse markets, including pharmaceuticals, food, agriculture, and industrial chemicals [5] - The company is also building next-generation biosecurity infrastructure and technologies to address global biological threats [5]

Company Presentation - Ginkgo Bioworks CEO Jason Kelly is scheduled to present at the 43rd Annual J P Morgan Healthcare Conference on January 16 2025 at 10 30 a m PT (1 30 p m ET) [1] - Further details webcast link and a replay of the presentation will be posted on the company's investor relations website [1] Company Overview - Ginkgo Bioworks is the leading horizontal platform for cell programming providing flexible end-to-end services across diverse markets including food and agriculture pharmaceuticals and industrial and specialty chemicals [2] - Ginkgo Biosecurity is building next-generation infrastructure and technologies to help global leaders predict detect and respond to biological threats [2] Contact Information - Investor contact email is provided for inquiries [3] - Media contact email is provided for inquiries [3]

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. ...